(MENAFN- NewsIn.Asia)
Oct 10 (AdaDerana) – Sri Lanka is planning to roll out Pfizer-BioNTech vaccines as the third dose for fully vaccinated people above 20 years of age, according to the State Minister of Production, Supply and Regulation of Pharmaceuticals.
Necessary measures have been taken to place a purchase order for 14.5 million doses of Pfizer-BioNTech vaccine, Prof. Channa Jayasumana said further.
For similar articles, join our Whatsapp group for the latest updates. – click here
Reportedly, the State Pharmaceuticals Corporation has entered an agreement with Pfizer Inc. yesterday for the procurement of more of its COVID-19 vaccines.
“As the first phase of this vaccination program, we will administer a third dose for those who are aged above 60 years and suffer from co-morbidities as well as to health workers and members of security forces.”
Speaking on the inoculation drive for children, the state minister said Pfizer doses will be rolled out at school premises for students in Advanced Level classes. Regional Directors of Health and District Epidemiologists have been given necessary instructions in this regard, he added.
One million more doses of the Pfizer vaccine will arrive in Sri Lanka in the coming three weeks and more batches are expected to arrive in November and December, the state minister said further.
Subscribe to our Whatsapp channel for the latest updates from around the world
READ: //newsin.asia/tata-to-pay-2-4-bln-to-regain-control-of-troubled-air-india///newsin.asia/internet-sensation-yohani-makes-salman-khan-sing-manike-mage-hithe-with-her-on-bigg-boss-15/Internet sensation Yohani makes Salman Khan sing Manike Mage Hithe with her on Bigg Boss 15
//newsin.asia/tag/covid-19/,
Covid-19 //newsin.asia/tag/pfizer/,
Pfizer //newsin.asia/tag/sri-lanka/,
Sri Lanka //newsin.asia/tag/vaccine/,
VaccineMENAFN09102021000191011043ID1102945758
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.